China Busts Counterfeit Plavix Ring In Ongoing Crackdown
This article was originally published in PharmAsia News
Executive Summary
First Viagra, then anticancer drugs, now a best-selling blood thinner. Plavix is the latest target to be unveiled in the nationwide hunt for fake drugs in China, where ring leaders are now using social media to mask their activities and cast a wide net around the vast country, targeting patients taking some of the most prescribed drugs from multinational drug makers.
You may also be interested in...
2016 Review: Pricing, R&D Issues Dominate China Commercial Arena
2016 was again another busy year on the commercial front in China, with market changes, new regulations, and ongoing pricing pressures all affecting the pharma sector. Meanwhile, the push for licensing deals, innovation, and international expansion continued apace.
When Crisis Hits, Sanofi Turns To Digital Transformation In China
Fallout can be an opportunity when both makers and service providers see the need to collaborate to solve China's acute and changing regulatory demand.
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.